Dr. Guvenc Kockaya
Management Team Member at ECONiX
Dr. Guvenc Kockaya is a medical doctor, health economist and angel investor. He has published several articles and posters in international journals or presented them in international congresses about market access in healthcare. He has worked in government, private industry and academia in the field of market access or health economics for Europe, Middle East, North Africa and Western Asia regions. Dr. Kockaya is the editor of the books titled “Pharmaceutical Market Access in Emerging Markets” and “Pharmaceutical Market Access in Developed Markets” which are still among the Top 100 Best Sellers (International) in Amazon under “Pharmaceutical & Biotechnology Industry (Kindle Store)”. He is now the Founder & Chair of Board of Reinves Capital which is a financing and investment company that operates with the aim of enabling entrepreneurs to access finance and investors to reach the right entrepreneurs at the right time. Dr. Kockaya is also the Founder & CEO of ECONiX Research which provides customized research services focused on market access, health economics and outcome research, medical affairs, and business development for healthcare companies.
ECONiX Research provides customized research services focused on market access, health economics and outcome research, medical affairs, and business development for healthcare companies. The specialized research services are designed to serve clients in Eastern Europe, the Middle East, North Africa, and Western Asia, with offices located in Estonia, Tunisia, and Turkiye.
ECONiX Research aims to help healthcare companies gain a deeper understanding of the unique market access, pricing, reimbursement regulatory and cultural environments of these regions and make informed decisions about their business strategies. Motto of ECONiX Research, “Build Knowledge, Secure Access,” reflects the commitment to providing the knowledge and insights to healthcare companies need to navigate complex regulatory landscapes and secure access to new markets.